JNJ vs NVS
Johnson & Johnson and Novartis AG, both Healthcare
Johnson & Johnson is the larger company at $550B against $296B. On trailing earnings NVS is the cheaper of the two at a P/E of 21.2 against 30.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year JNJ returned +53% against +20% for NVS. The RyuScore puts NVS ahead, 74 against 69 out of 100.
| Figure | JNJ | NVS |
|---|---|---|
| Last close | $261 | $144 |
| Market cap | $550B | $296B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 30.3 | 21.2 |
| Dividend yield | 2.0% | n/a |
| 1-year return | +53% | +20% |
| 5-year return | +80% | +103% |
| RyuScoresector-relative, 1–10 | 69/100 | 74/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Johnson & Johnson
Revenue of $25B in Q2 2026, net income $5.5B. Its largest reported line is DARZALEX, 19% of the disclosed total.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.